Ashton Pharmaceuticals to produce new antianxiety drug for UK market
Ashton Pharmaceuticals, the UK subsidiary of US-based speciality pharmaceutical drug delivery company Inyx, has been selected by a British speciality pharmaceutical company to manufacture a new antianxiety drug for the UK market.
Ashton initially provided process development services to enable production scale-up to commercial batch sizes on the new drug. The company will now manufacture and package the entire production of this tablet product.
"We are very pleased that Inyx has been selected for the commercial production of this client's new product," said Dr Jack Kachkar, chairman of Inyx. "This reflects Ashton's in-depth capabilities to enable clients to bring new products rapidly to market." He added that another new product from this client is also under discussion for Ashton.